Company expects 2026 e-commerce business to grow 10% to 15% year-over-year
Ingredient business expected to be lower than prior year due to competitive market
Company anticipates higher 2026 operating expenses as it invests in strategic priorities
Overview
U.S. bioscience firm's Q2 net sales declined and missed analyst expectations
Q2 net income was $1.0 mln, down from $3.6 mln a year earlier
Company launched pharmaceutical program for rare diseases and at-home telehealth platform
Result Drivers
Direct-to-consumer growth - Co said direct-to-consumer sales on its website grew 23% year-over-year, led by Tru Niagen
New business initiatives - Co launched Niagen Plus telehealth platform and pharmaceutical program targeting rare genetic diseases and aging disorders
Analyst coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
NAGE•
